Stockscreener 앱 받기
13.51
7.99%
1.00
시간 외 거래:
13.56
0.05
+0.37%
전일 마감가:
$12.51
열려 있는:
$12.8
하루 거래량:
2.25M
Relative Volume:
1.60
시가총액:
$296.01M
수익:
-
순이익/손실:
$-112.46M
주가수익비율:
-8.2378
EPS:
-1.64
순현금흐름:
$-99.89M
1주 성능:
+61.60%
1개월 성능:
+34.97%
6개월 성능:
+270.95%
1년 성능:
-31.85%
1일 변동 폭
$12.61
$14.21
1주일 범위
$8.9477
$14.21
52주 변동 폭
$2.622
$65.80
보 바이오파마 Stock (VOR) Company Profile
명칭
Vor Biopharma Inc
전화
617-655-6580
주소
500 BOYLSTON STREET, BOSTON
VOR을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VOR
Vor Biopharma Inc
|
13.51 | 274.10M | 0 | -112.46M | -99.89M | -1.64 |
|
VRTX
Vertex Pharmaceuticals Inc
|
455.71 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
752.62 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
850.95 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
391.50 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.92 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
보 바이오파마 Stock (VOR) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | JP Morgan | Overweight |
| 2025-11-25 | 재개 | Wedbush | Neutral |
| 2025-10-15 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2025-09-24 | 업그레이드 | Stifel | Hold → Buy |
| 2025-06-30 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
| 2022-07-26 | 개시 | Wedbush | Outperform |
| 2022-04-27 | 개시 | Goldman | Neutral |
| 2021-12-17 | 개시 | H.C. Wainwright | Buy |
| 2021-12-03 | 개시 | Robert W. Baird | Outperform |
| 2021-12-02 | 개시 | Oppenheimer | Outperform |
| 2021-10-19 | 개시 | JMP Securities | Mkt Outperform |
| 2021-03-25 | 개시 | B. Riley Securities | Buy |
| 2021-03-03 | 개시 | Barclays | Overweight |
| 2021-03-03 | 개시 | Evercore ISI | Outperform |
| 2021-03-02 | 개시 | Goldman | Sell |
| 2021-03-02 | 개시 | Stifel | Buy |
모두보기
보 바이오파마 주식(VOR)의 최신 뉴스
Vor Biopharma (VOR) Stock Jumps Over 30% After JPMorgan Upgrade: What December 2025’s Rally Really Means for Investors - ts2.tech
Aug Chart Watch: Why Vor Biopharma Inc stock remains resilientPortfolio Performance Report & Free Technical Confirmation Trade Alerts - moha.gov.vn
Vor Biopharma Launches $150 Million Private Placement; Shares Rise - marketscreener.com
Vor Bio announces $150M private placement - MSN
Vor Bio Announces $150 Million Private Placement - Yahoo Finance
Manufacturing Stocks To Keep An Eye OnDecember 9th - MarketBeat
Vor Biopharma (VOR) Is Up 45.6% After Telitacicept Phase 3 Win And JPMorgan Nod Has The Bull Case Changed? - Yahoo Finance
VOR shares rally over 40% in pre-market trade after JPMorgan initiates bullish coverage - MSN
Vor Biopharma approves stock option repricing plan - MSN
Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price (VOR) - Seeking Alpha
Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage - Yahoo Finance
Vor Biopharma’s Recent Developments: Stock Impact Analyzed - StocksToTrade
Biotech stock soars 40% on JPMorgan’s bold call - Rolling Out
Vor Biopharma (VOR) Surges on J.P. Morgan's Bullish Outlook - GuruFocus
Vor Bio stock gains bullish view at J.P. Morgan (VOR:NASDAQ) - Seeking Alpha
Vor Biopharma (VOR) Stock Surges as JPMorgan Just Made a Massive Call on This Biotech - parameter.io
Vor Biopharma’s Telitacicept: A Promising Buy Amidst Valuation Disconnect and Strategic Focus on Unmet Needs - TipRanks
Vor Biopharma (VOR) Stock Explodes 40% as JPMorgan Sees Massive Upside Ahead - Blockonomi
Vor Biopharma Stock Surge: Strategic Move or Short-Lived Spike? - timothysykes.com
Vor Biopharma reprices stock options for employees and executives By Investing.com - Investing.com South Africa
Vor Biopharma (NASDAQ:VOR) Now Covered by Analysts at JPMorgan Chase & Co. - MarketBeat
Vor Biopharma Approves Stock Option Repricing Plan - TipRanks
Vor Biopharma reprices stock options for employees and executives - Investing.com
VOR Shares Rally Over 40% In Pre-Market Trade After JPMorgan Initiates Bullish Coverage - Stocktwits
JPMorgan Initiates Vor Biopharma at Overweight With $43 Price Target - marketscreener.com
Pre Market Movers: XCUR, VOR, MTVA Set The Path - RTTNews
JP Morgan Initiates Coverage on Vor Biopharma (VOR) with Overwei - GuruFocus
Vor Bio jumps as J.P.Morgan initiates with 'overweight' rating - TradingView
Vor Bio initiated with an Overweight at JPMorgan - TipRanks
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target By Investing.com - Investing.com South Africa
JPMorgan initiates Vor Biopharma stock with Overweight rating on telitacicept potential - Investing.com
JPMorgan initiates Vor Biopharma stock with Overweight rating, $43 target - Investing.com
Vor Biopharma (NASDAQ:VOR) Expands Innovation In Hematologic Therapy - Kalkine Media
JPMorgan Starts Vor Biopharma, Inc. (VOR) at Overweight - StreetInsider
Profit Review: Will Vor Biopharma Inc stock maintain momentum in 2025 - moha.gov.vn
Vor Biopharma slumps 26%, prices $100M equity at $10 per share - MSN
Will Vor Biopharma Inc. stock maintain momentum in 2025Gold Moves & Capital Efficiency Focused Strategies - Newser
What drives Vor Biopharma Inc stock priceEarnings Surprise Analysis & Superior Capital Trading Plans - earlytimes.in
Is There An Opportunity With Vor Biopharma Inc.'s (NASDAQ:VOR) 49% Undervaluation? - Yahoo Finance
Vor Biopharma Inc. (NASDAQ:VOR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
Form 424B3 Vor Biopharma Inc. - StreetInsider
Wedbush Predicts Vor Biopharma's Q4 Earnings (NASDAQ:VOR) - MarketBeat
How Vor Biopharma Inc. stock benefits from global expansionLayoff News & Fast Exit and Entry Strategy Plans - BỘ NỘI VỤ
Wedbush Begins Coverage on Vor Biopharma (NASDAQ:VOR) - MarketBeat
Vor Biopharma (VOR) Upgraded to Buy: Here's What You Should Know - sharewise.com
Wedbush Initiates Coverage on Vor Biopharma (VOR) with Neutral R - GuruFocus
Wedbush Boosts Price Target on Vor Biopharma to $9 From $0.40, Keeps Neutral Rating - marketscreener.com
Wedbush Assumes Vor Biopharma, Inc. (VOR) at Neutral - StreetInsider
Vor Biopharma Inc. (VOR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Vor Biopharma Inc. stock attract more institutional investorsWeekly Trade Review & Capital Efficiency Focused Strategies - newser.com
Why retail investors favor Vor Biopharma Inc. stock2025 Technical Patterns & Free Community Supported Trade Ideas - newser.com
보 바이오파마 (VOR) 재무 분석
매출
순이익
현금흐름
주당 순 이익
보 바이오파마 주식 (VOR) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 28 '25 |
Sale |
27.42 |
124,311 |
3,408,230 |
1,055,749 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 30 '25 |
Sale |
25.12 |
24,579 |
617,424 |
779,652 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 27 '25 |
Sale |
28.12 |
90,941 |
2,557,261 |
1,180,060 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 23 '25 |
Sale |
28.01 |
76,880 |
2,153,409 |
1,324,346 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 24 '25 |
Sale |
28.01 |
53,345 |
1,494,193 |
1,271,001 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 20 '25 |
Sale |
29.67 |
92,023 |
2,730,483 |
0 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Oct 21 '25 |
Sale |
28.11 |
25,027 |
703,509 |
1,401,226 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 17 '25 |
Sale |
30.25 |
25,717 |
777,987 |
1,178,725 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 20 '25 |
Sale |
30.05 |
11,616 |
349,101 |
1,167,109 |
| Reprogrammed Interchange LLC | 10% Owner |
Oct 21 '25 |
Sale |
30.07 |
200 |
6,015 |
1,166,909 |
0.36%
1.12%
자본화:
|
볼륨(24시간):